Tolerability to HS-20004 With Titration Administration in Type 2 Diabetic Patients
- Registration Number
- NCT02750007
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Brief Summary
This study is conducted in China. The aim of this trial is to assess the tolerability to HS-20004 with titration administration in type 2 diabetic patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
- Type 2 diabetes diagnosed for more than 3 months;
- HbA1c between ≥6.0 and ≤9.0 %, and FPG between ≥7.0 and ≤13.9 mmol/L;
- Body Mass Index (BMI) between 18.5 and 30 kg/m^2 (inclusive) with a total body weight of at least 50 kg;
- Agree to stop any other drugs for diabetes during washout and study period;
Exclusion Criteria
- Treatment of GLP-1 analogues, DPP-IV enzyme inhibitors or other analogues before;
- History or family history of drug allergy;
- Smoker or alcohol abuse;
- Currently use or plan to use systemic corticosteroid;
- History of recurrent severe hypoglycemia;
- History of proliferative retinopathy or maculopathy which required acute treatment;
- Impaired hepatic or renal function, or cardiac problem;
- Uncontrolled active or untreated hypertension;
- Family history of thyroid cancer or submandibular gland cancer, or past history of pancreatitis, cholelithiasis, or serious unconscious hypoglycemia history;
- Positive of hepatitis B surface antigen, hepatitis C antibody, HIV antibody or syphilis antibody;
- Subject has participated in any investigational study within 3 months, or is currently participating in another clinical study;
- Female subject of childbearing potential who does not use an acceptable method of birth control, is pregnant or planning a pregnancy, or breastfeeding, or male subject who does not use an acceptable method of birth control, within six months before randomization; Subject who cannot refrain from smoking, eating and/or drinking containing xanthine/caffeine, or strenuous exercise, or others that affect drug absorption, distribution, metabolism and excretion within 2 days before the study drug administration;
- Have any other medical abnormality (such as cardiovascular, hepatic, renal, gastrointestinal, immunologic, hematological, hormonal, metabolic, neoplasmatic or mental disease), which in the opinion of the investigator, might affect the absorption, distribution, metabolism, and excretion of the study drug, or prevent the patient from following and completing the protocol；
- Subject was not used for the study as determined by the Investigator.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Experimental HS-20004 Weekly-dose titration from 0.04mg/day HS-20004 to the maximum tolerable dose or of the ultimate 0.18mg/day
- Primary Outcome Measures
Name Time Method Number of Treatment Emergent Adverse Events(TEAEs) through study completion, an maximum of 8 weeks
- Secondary Outcome Measures
Name Time Method Number of Nausea and vomiting during titration through study completion, an maximum of 8 weeks Change in plasma concentration of glucose from baseline at different dose steps through study completion, an maximum of 8 weeks Change in plasma concentration of insulin from baseline at different dose steps through study completion, an maximum of 8 weeks Change in plasma concentration of glucagon from baseline at different dose steps through study completion, an maximum of 8 weeks The minimum dose of HS-20004 that could keep plasma glucose under 6.1 mmol/L in Type 2 Diabetic Patients through study completion, an maximum of 8 weeks Mean Change From Baseline in Body Weight at different dose steps through study completion, an maximum of 8 weeks Change in plasma concentration of HS-20004 from baseline at different dose steps through study completion, an maximum of 8 weeks
Trial Locations
- Locations (1)
The Second Xiangya Hospital of Central South University
🇨🇳Changsha, Hunan, China